Adage Capital Partners Gp, L.L.C. Bellus Health Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $969,000 - $1.5 Million	-150,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.26 - $8.3 $1.32 Million - $2.08 Million	-250,000 Reduced 62.5%	150,000 $1.21 Million
Q3 2021 Nov 15, 2021	SELL	$2.7 - $6.64 $2.7 Million - $6.64 Million	-1,000,000 Reduced 71.43%	400,000 $2.46 Million
Q1 2021 May 17, 2021	BUY	$3.03 - $4.58 $4.24 Million - $6.41 Million	1,400,000 New	1,400,000 $5.38 Million
Q2 2020 Aug 14, 2020	SELL	$8.88 - $11.15 $5.33 Million - $6.69 Million	-600,000 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$5.77 - $10.85 $4.04 Million - $7.6 Million	-700,000 Reduced 53.85%	600,000 $5.99 Million
Q3 2019 Nov 14, 2019	BUY	$6.24 - $8.84 $8.11 Million - $11.5 Million	1,300,000 New	1,300,000 $8.31 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.